Neuronetics Stock Forecast, Price & News

-0.48 (-2.98 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume165,301 shs
Average Volume273,781 shs
Market Capitalization$402.63 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive STIM News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

Neuronetics logo

About Neuronetics

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.70 out of 5 stars

Medical Sector

328th out of 2,099 stocks

Surgical & Medical Instruments Industry

29th out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Neuronetics (NASDAQ:STIM) Frequently Asked Questions

Is Neuronetics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neuronetics stock.
View analyst ratings for Neuronetics
or view top-rated stocks.

What stocks does MarketBeat like better than Neuronetics?

Wall Street analysts have given Neuronetics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Neuronetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Neuronetics?

Neuronetics saw a increase in short interest during the month of May. As of May 14th, there was short interest totaling 1,210,000 shares, an increase of 68.6% from the April 29th total of 717,800 shares. Based on an average daily volume of 454,000 shares, the short-interest ratio is presently 2.7 days.
View Neuronetics' Short Interest

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Neuronetics

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) released its earnings results on Tuesday, May, 4th. The company reported ($0.31) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.31). Neuronetics had a negative net margin of 45.39% and a negative trailing twelve-month return on equity of 49.29%.
View Neuronetics' earnings history

How has Neuronetics' stock price been impacted by Coronavirus (COVID-19)?

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STIM shares have increased by 655.1% and is now trading at $15.63.
View which stocks have been most impacted by COVID-19

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics issued an update on its FY 2021 earnings guidance on Tuesday, May, 18th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $59 million-$63 million, compared to the consensus revenue estimate of $60.67 million.

What price target have analysts set for STIM?

5 brokers have issued 1-year target prices for Neuronetics' shares. Their forecasts range from $21.00 to $25.00. On average, they anticipate Neuronetics' share price to reach $22.50 in the next year. This suggests a possible upside of 44.0% from the stock's current price.
View analysts' price targets for Neuronetics
or view top-rated stocks among Wall Street analysts.

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:
  • Mr. Keith J. Sullivan, Pres, CEO & Director (Age 63, Pay $832.67k)
  • Mr. Stephen J. Furlong M.S., Sr. VP, CFO & Treasurer (Age 56, Pay $701.67k)
  • Mr. W. Andrew Macan, Sr. VP, Gen. Counsel, Chief Compliance Officer, Sec. & Member of Office of the Pres (Age 48, Pay $692.61k)
  • Ms. Janie Bates, VP of Marketing
  • Ms. Sara Grubbs, VP of Sales
  • Ms. Kara Thornton, VP of HR & Sr. Director

Who are some of Neuronetics' key competitors?

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Polar Capital Holdings Plc (4.85%), Archon Capital Management LLC (4.71%), First Light Asset Management LLC (4.46%), Parian Global Management LP (4.39%), Royce & Associates LP (3.99%) and Granite Point Capital Management L.P. (2.78%). Company insiders that own Neuronetics stock include Brian E Farley, Bruce Joseph Shook, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Keith J Sullivan, Sheryl L Conley, Stephen Furlong, Stephen M Campe and William Andrew Macan.
View institutional ownership trends for Neuronetics

Which institutional investors are selling Neuronetics stock?

STIM stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Interwest Venture Management Co., DAFNA Capital Management LLC, Millrace Asset Group Inc., Friess Associates LLC, David J Yvars Group, Bank of New York Mellon Corp, and Renaissance Technologies LLC. Company insiders that have sold Neuronetics company stock in the last year include Bruce Joseph Shook, Gregory Harper, Keith J Sullivan, Sheryl L Conley, and Stephen Furlong.
View insider buying and selling activity for Neuronetics
or view top insider-selling stocks.

Which institutional investors are buying Neuronetics stock?

STIM stock was purchased by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, First Light Asset Management LLC, Parian Global Management LP, Redmile Group LLC, G2 Investment Partners Management LLC, Premier Fund Managers Ltd, Morgan Stanley, and Millennium Management LLC. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Stephen Furlong, Stephen M Campe, and William Andrew Macan.
View insider buying and selling activity for Neuronetics
or or view top insider-buying stocks.

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $15.63.

How much money does Neuronetics make?

Neuronetics has a market capitalization of $402.63 million and generates $49.24 million in revenue each year. The company earns $-27,450,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis.

How many employees does Neuronetics have?

Neuronetics employs 147 workers across the globe.

What is Neuronetics' official website?

The official website for Neuronetics is

Where are Neuronetics' headquarters?

Neuronetics is headquartered at 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at (610) 640-4202 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.